**Abstract**

**Introduction:** No meta-analysis has evaluated azapirones (serotonin 1A receptor partial agonists) as anxiolytics for attention deficit hyperactivity disorder (ADHD).

**Methods:** Randomized controlled trials (RCTs) and single-arm trials published before 2015/10/27 were retrieved from major healthcare databases and clinical trial registries. Relative risk and 95% confidence intervals were calculated.

**Results**: Five RCTs (n = 429) and two single-arm studies (n = 62) were identified. Three RCTs compared buspirone versus methylphenidate in children/adolescents, one buspirone patches versus placebo patches in children/adolescents, and one atomoxetine plus buspirone versus atomoxetine versus placebo in adults. The single-arm studies were buspirone trails in children/adolescents. All-cause discontinuation rates and adverse events did not differ between pooled buspirone and methylphenidate groups. No other meta-analyses of buspirone efficacy and safety versus comparators were conducted due to insufficient data. Two RCTs found no significant differences in parent and teacher ADHD-Rating Scale total scores between buspirone and methylphenidate, while one reported that methylphenidate improved parent and teacher ADHD-RS total scores versus buspirone.

**Discussion:** It has remained unclear whether buspirone use has benefit for ADHD patients and therefore further evidence is needed for better clinical use of buspirone in patients with ADHD.
